Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

Bioengineers develop nano-delivery system for cancer therapy

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

2 Nov 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Clemson bioengineer designing new ways to target drugs

Clemson bioengineer Frank Alexis is designing new ways to target drugs and reduce the chances for side effects.

9 Oct 2009

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced that they have received a notice of allowance from the U.S. Patent and Trademark Office for its first U.S. patent application.

8 Oct 2009

Scientists develop new molecule that can deliver genetic-based drugs into cells

Theresa M. Reineke, associate professor of chemistry in the College of Science, and colleagues in her lab at Virginia Tech and at the University of Cincinnati have developed a new molecule that can travel into cells, deliver genetic cargo, and packs a beacon so scientists can follow its movements in living systems.

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

PharmaNova to announce new technology breakthroughs at the 2009 AAPS annual meeting

PharmaNova, a leader in nanotechnology-based Drug Delivery Systems, is due to exhibit at the 2009 annual meeting of the American Association of Pharmaceutical Scientists (AAPS) scheduled in Los Angeles, CA, from November 8 - 12.

1 Oct 2009

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009

An overview on nanoparticles

At SINTEF scientist both exploit the benefits of the nanotechnology and try to discover how tiny particles could behave hazardous in nature.

28 Sep 2009

Titanium dioxide nanoparticles catalyze brain tumor death

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.

23 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

23 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

Nanoparticle News and Research

Further Reading

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Nanoparticles may cause DNA damage across a cellular barrier

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Abraxis Health dedicates its new manufacturing facility in Phoenix

Bioengineers develop nano-delivery system for cancer therapy

Researchers develop magneto-nano sensor chip to detect cancer

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Clemson bioengineer designing new ways to target drugs

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Scientists develop new molecule that can deliver genetic-based drugs into cells

Scientists create new technology to improve detection of leukemia cells in bone marrow

PharmaNova to announce new technology breakthroughs at the 2009 AAPS annual meeting

SATAI invests $1.045 million in Azaya Therapeutics

An overview on nanoparticles

Titanium dioxide nanoparticles catalyze brain tumor death

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery